Systemic sclerosis & Raynaud's
Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from the German Network for systemic sclerosis (SSc) cohort
Authors' conclusion
SSc treatment has evolved over the past 25 years, with prescribing patterns increasingly reflecting evidence and guideline recommendations.
Study context
- Population
- Patients with SSc in the German Network for SSc (DNSS) cohort
- Participants
- 6,583 patients
- Outcome
- Trends in vasoactive, immunomodulatory and antifibrotic therapy; variation between centres and specialties; co-prescription patterns; clinical predictors of treatment
Methodological detailsmulticentre registry, multivariable mixed models
- Multicentre registry
- Multivariable mixed models
Main finding
As reported in the abstract
Treatment patterns over time
Use of endothelin receptor antagonists and prostanoids / prostacyclin receptor agonists, 2005
3.0%
95% CI 1.5%–5.3%
Use of endothelin receptor antagonists and prostanoids / prostacyclin receptor agonists, 2025
28.4%
25.5%–31.3%
GC use, 2000
50.0%
31.9%–68.1%
GC use, 2025
18.1%
11.8%–25.9%
Observational data: associations, not effects.
Original publication
Real-world treatment patterns and determinants of therapy in systemic sclerosis: findings from the German Network for SSc cohort. Arthritis Res Ther. Published 10 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →